Skip to main content

Delayed Sleep Phase Syndrome clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • Lemborexant in Delayed Sleep Phase Syndrome

    open to eligible people ages 18 years and up

    The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy. In this 2-year study, we will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.

    Redwood City, California

Last updated: